Cannabidiol for the prevention and treatment of graft-versus-host disease
The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
1. A method of preventing, ameliorating or treating graft-versus-host disease (GVHD), comprising the step of administering to a patient undergoing transplantation, either within 14 days prior to transplantation or beginning 1 to 30 days after transplantation, an effective amount of a composition lacking psychotropic effects comprising cannabidiol in doses of cannabidiol between about 5 mg to about 600 mg each administration, once to three times daily.
2. The method according to claim 1 wherein said GVHD is acute GVHD.
3. The method according to claim 1 wherein said GVHD is chronic GVHD.
4. The method according to claim 1 , wherein said patient is undergoing allogeneic hematopoietic stem cell transplantation.
5. The method according to claim 4 , wherein said patient is undergoing allogeneic hematopoietic stem cell transplantation in which the cells are bone marrow stem cells, peripheral-blood hematopoietic stem cell grafts, cord blood units, haploidentical peripheral-blood stem cells or haploidentical bone marrow stem cells.
6. The method according to claim 1 , wherein said composition lacking psychotropic effects further comprises at least one additional therapeutic agent.
7. A method of treating graft-versus-host disease (GVHD), comprising administering to a patient suffering from GVHD a therapeutically effective amount of a composition lacking psychotropic effects comprising cannabidiol in doses of cannabidiol between about 5 mg to about 600 mg each administration, once to three times daily.
8. The method according to claim 7 , wherein said patient is suffering from acute GVHD.
9. The method according to claim 7 , wherein said patient is suffering from chronic GVHD.
10. The method according to claim 7 , wherein said composition lacking psychotropic effects further comprises at least one additional therapeutic agent.
11. The method according to claim 1 , wherein said administering comprises orally administering.
12. The method according to claim 7 , wherein said administering comprises orally administering.